The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.

The upcoming spin-off of The Handmaid's Tale, The Testaments, hasn't confirmed Elisabeth Moss's return as June, but she ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.

In the midst of the nationwide “No Kings” movement on Saturday, dozens of women walked the streets silently in red handmaid’s costumes in Fort Worth holding up the sign “We the people were not meant ...